NCT04929028 2026-03-18
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06770582 2026-03-18
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06919965 2026-03-13
MoonRISe-3
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT04847063 2026-03-06
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT05672108 2026-03-05
Phase II Trial of Lung Chemoemobolization
City of Hope Medical Center
Phase 2 Recruiting
NCT06513065 2026-02-19
HIPEC-PMP
University of Southampton
Phase 3 Recruiting
NCT05838391 2026-02-03
Adaptive Radiation in Anal Cancer
Columbia University
Phase NA Recruiting
NCT07097142 2026-02-02
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology
Phase 3 Recruiting
NCT06774131 2026-01-16
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
UroGen Pharma Ltd.
Phase 3 Recruiting
NCT04779554 2025-12-24
Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
University of Kentucky
Phase 2 Recruiting